Skip to main content
. Author manuscript; available in PMC: 2024 Jan 11.
Published in final edited form as: Expert Rev Pharmacoecon Outcomes Res. 2022 Apr 18;22(6):891–911. doi: 10.1080/14737167.2022.2060823

Table 4.

Summary of case report results and adverse events.

Citation Patient
case
reports
included
Mean
follow-up
time
% pts
survived
% able to
complete
treatment, once
started
Among those who completed
treatment, % who are
symptom free from SCD
% patients who
became transfusion
independent
# of patients with severe AEs (list)
NCT02151526 1 15 months 1 1 1 1 1
  • grade 4 neutropenia

  • grade 3 anemia

  • grade 3 thrombocytopenia

  • grade 3 infection with Staphylococcus epidermidis (with positive results on blood culture)

NCT03745287 1 16.6 months 1 1 1 1 1
  • sepsis in the presence of neutropenia

  • cholelithiasis

  • abdominal pain

NCT03282656 6 18 months 6 6 6 5 3
  • hospital admission for less than 24 hours for fever and influenza infection

  • recurrent priapism leading to two hospital admissions

  • leg pain leading to a readmission for less than 24 hours

NCT02140554 2 2 2 2
  • myelodysplastic syndrome

  • acute myeloid leukemia

NCT04293185 1 1 1 1
  • myelodysplastic syndrome